WuXi Biologics

2488 employees

WuXi Biologics is a open-access technology platform company offering end-to-end solutions to empower organizations to discover and develop.

Investor insights

Sectors invested in

Biotechnology6

Medical3

Biopharma3

biotechnology and veterinary medicine2

Health Care2

Therapeutics2

Veterinary2

autoimmune2

Oncology2

biotech2

Funding rounds participated in

$15M sweet spot round size

Most of their 7 investments are in rounds between $14M and $40M

Basic info

Industry

pharmaceutical manufacturing

Sectors

biotherapeutics

Cell Line Development

vaccine development

Biologics conjugation

biopharmaceuticals

antibody manufacturing

Analytical Characterization

Pharmaceutical

Formulation Development

continuous manufacturing

Bioprocess CMC

Biosafety

Biologics discovery service

Biologics GMP Manufacturing

Health Care

Cell Culture and Purification Process Development

analytical services

antibody discovery

vaccine manufacturing

Monoclonal Antibodies (mAbs)

protein production

Date founded

2010

Investments made

Innolake Biopharm raised $14M on June 5, 2023

Investors: WuXi Biologics

Duality Biologics raised $90M on May 19, 2021

Investors: 华盖资本有限责任公司, GREEN PINE CAPITAL PARTNERS, Lilly Asia Ventures and WuXi Biologics

Innolake Biopharm raised $46M on January 1, 2021

Investors: 华盖资本有限责任公司, CDH Investments and WuXi Biologics

Invetx raised $10M on September 30, 2020

Investors: Anterra Capital, Casdin Capital, LLC, AbCellera and WuXi Biologics

Invetx raised $15M on February 24, 2020

Investors: Anterra Capital, AbCellera and WuXi Biologics

Undisclosed raised $40M on May 21, 2019

Investors: Lilly Asia Ventures, RA Capital Management, L.P., Viking Global Investors and WuXi Biologics

Duoning raised $15M on April 23, 2019